Results 151 to 160 of about 36,154,612 (288)

Study Protocol [PDF]

, 2020
openaire   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

The pharmacist's role in the periprocedural management of anticoagulation in Canada: A qualitative study protocol. [PDF]

PLoS One
Okpalaora CS, Young SW, Lee TA.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

A feasibility study of behavioural activation for haemodialysis: The BEACH study protocol. [PDF]

PLoS One
Carswell C, Metcalfe S, Agyekum R, Awan F, Bhandari S, Bramham K, Chilcot J, Millar J, Gega L.   +8 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Study protocol for first national vasa previa perinatal registry. [PDF]

PLoS One
Paulosky KE, Santos-Roca A, Corbetta-Rastelli C, Cudjoe E, Esterquest D, Fadairo O, Fickau BA, Funfar B, Perelman A, Ross N, Sibbald CA, Todhunter L, Waites BT, Chon AH, DeBolt CA, Drennen K, Hanks L, Jelin AC, Kush M, Lynch T, Malshe A, Miller LA, Munoz JL, Norton ME, Rincon M, Roman AS, Russo M, St Onge R, Oyelese Y, Steinberg G, Toscano M.   +30 more
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study

, 2017
Background Dose escalation of SBRT for locally advanced pancreatic cancer patients had been reported in several studies in one or three fractions, and phase I protocol was developed to investigate the maximum tolerated dose with ...
Ju, Xiao-Ping, Qing, Shui-Wang, Cao, Yang-Sen, Zhang, Huo-Jun   +3 more
core  

Sexual health and REhabilitation online (SHAREonline): study protocol of an optimisation trial. [PDF]

BMJ Open
Miklos EM, Recklitis CJ, Reese JB, Medeiros-Nancarrow C, Bober SL.   +4 more
europepmc   +1 more source